Empliciti

Active Ingredient(s): Elotuzumab
FDA Approved: * November 30, 2015
Pharm Company: * BRISTOL MYERS SQUIBB
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Empliciti Overview

Elotuzumab (brand name Empliciti, (Bristol-Myers Squibb and AbbVie), previously known as HuLuc63) is a humanized monoclonal antibody used in relapsed multiple myeloma.[1] The package insert denotes its mechanism as a SLAMF7-directed (also known as CD 319) immunostimulatory antibody.[2] Contents 1 Approvals and indications 1.1 Multiple myeloma 2 References 3 External links Approvals and indications Multiple myeloma In May 2014, it was granted "Bre...

Read more Empliciti Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Elotuzumab

Recent Empliciti Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Elotuzumab
  • Injection: 300mg, 400mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Empliciti: (2 results)

Sorted by National Drug Code
  • 0003-2291 Empliciti 300 mg Intravenous Injection, Powder, Lyophilized, for Solution by E.r. Squibb & Sons, L.L.C.
  • 0003-4522 Empliciti 400 mg Intravenous Injection, Powder, Lyophilized, for Solution by E.r. Squibb & Sons, L.L.C.

Other drugs which contain Elotuzumab or a similar ingredient: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 19 April 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA